Abstract:Wenjuan Wang, 1 Juanjuan Liang, 1 Rong Fan, 2 Yuanqing Cai, 3 Baisong Yin, 1 Yangyi Hu 1 1 School of Government, Central University of Finance and Economics, Beijing, 100081, People's Republic of China; 2 Peking University Cancer Hospital & Institute, Beijing, 100142, People's Republic of China; 3 Chinese Academy of Social Sciences Evaluation Studies, Beijing, 100732, People's Republic of China Correspondence: Yangyi Hu, School of Government, Central University of Finance and Economics, 39 South College Road, Beijing, 100081, People's Republic of China, Email Purpose: The medical–pharmaceutical separation (MPS) reform is a healthcare reform that focuses on reducing the proportion of drug expenditure. This study aims to analyze the impact of the MPS reform on hospitalization expenditure and its structure in tertiary public hospitals. Methods: Using propensity score matching and multi-period difference-in-difference methods to analyze the impact of the MPS reform on hospitalization expenditure and its structure, a difference-in-difference-in-difference model was established to analyze the heterogeneity of whether the tertiary public hospital was a diagnosis-related-group (DRG) payment hospital. Of 22 municipal public hospitals offering tertiary care in Beijing, monthly panel data of 18 hospitals from July 2011 to March 2017, totaling 1242 items, were included in this study. Results: After the MPS reform, the average drug expenditure, average Western drug expenditure, and average Chinese drug expenditures per hospitalization decreased by 24.5%, 24.6%, and 24.1%, respectively (P < 0.001). The proportions of drug expenditure decreased by 4.5% (P < 0.001), and the proportion of medical consumables expenditure increased significantly by 2.7% (P < 0.001). Conclusion: The MPS reform may significantly optimize the hospitalization expenditure structure and control irrational increases in expenditure. DRG payment can control the tendency to increase the proportions of medical consumables expenditure after the reform and optimize the effect of the reform. There is a need to strengthen the management of medical consumables in the future, promote the MPS reform and DRG payment linkage, and improve supporting measures to ensure the long-term effect of the reform. Keywords: diagnosis-related-group, provider payment reforms, healthcare expenditure, propensity-score-matching, difference-in-difference-in-difference, China In most developed countries, drug expenditure generally comprises no more than 25% of the total medical expenditure, with the proportion being no more than 30% in Southeast Asian countries. However, in 2015, the proportion was as high as 31.34% in China. 1 The primary reason for this high proportion is that, at the time of the founding of New China, financial resources were insufficient to subsidize hospital income. For sustainable development of hospitals, medical institutions were allowed to mark up the prices of drugs by no more than 15%. Subsequently, drug income became the main source of medical income. 2 A high proportion of drug expenditure in total medical expenditure carries the potential risk of irrational medicine use, affecting patients' health. 3 Moreover, the excessively high drug expenditure brings a heavy economic burden to patients. 4–8 To improve this situation, since the proposed implementation of the medical–pharmaceutical separation (MPS) reform in 2009, a realistic method to abolish drug markups in public hospitals has been explored across the country. 9 In 2012, the Beijing Municipality began implementing the MPS reform in five hospitals, including Youyi Hospital. The MPS reform's main measures include the abolition of the drug markup, cancellation of registration and consultation expenditures, and establishment of medical service expenditure, aimed at reducing the proportion of drug expenditure in total medical expenditure and increasing that of medical service expenditure. This process maintains the link between healthcare, medicine, and healthcare insurance and strengthens the reform of healthcare insurance coverage and payment methods to reduce the burden on patients. Since 2017, this reform has been implemented in public and voluntary private medical institutions across Beijing. Most existing studies confirm that the MPS reform has helped control medical expenditure, optimize the expenditure structure, and standardize medical practices. However, some studies indicate some of the challenges that the reform continues to face, such as the limited effect of the reform in controlling expenditure, over-reliance on government financial compensation, an -Abstract Truncated-

Impact of separating drug sales from medical services reform on Beijing Cancer Hospital from the perspective of medical insurance data

The Impact of Separating Drug and Medical Service on the Hospitalization Expense of Patients with Medical Insurance in Pilot Hospitals of Beijing

The impact of separating drug sales from medical services reform on mechanism of controlling outpatient and emergency expenses in Beijing

Research on the impact of the clinic-pharmacy separation reform in Beijing on the economic burden of insured outpatients

The Impact of a Pilot Reform on the Diagnosis-Related-groups Payment System in China: a Difference-in-difference Study

Evaluation of Targeted Anticancer Agents Incorporated into Medical Insurance Policy: Taking a Tertiary Oncology Institution in Beijing as an Example

Impact of China's Healthcare Price Reforms on Traditional Chinese Medicine Public Hospitals in Beijing: an Interrupted Time-Series Study

Does the separating of hospital revenue from drug sales reduce the burden on patients? Evidence from China

Impact of Medical–Pharmaceutical Separation Reform on Hospitalization Expenditure in Tertiary Public Hospitals: Difference-in-Difference Analysis Based on Panel Data from Beijing

PCN43 STUDY ON MEDICAL EXPENDITURE AND PAYMENT PATTERNS OF INSURED PATIENTS WITH CANCER IN CHINA

Effect of separating drug sales from medical services on hospital revenue and medical services in the county public hospitals of Guangxi Province

Analysis of the composition and influencing factors of hospitalization expenses for 1517 patients with lung malignant tumors in Beijing

The impacts of public hospital comprehensive reform policies on hospital medicine cost, revenues and healthcare expenditures 2014–2019: An analysis of 103 tertiary public hospitals in China

Effects of Chinese medical pricing reform on the structure of hospital revenue and healthcare expenditure in county hospital: an interrupted time series analysis

Short-term and long-term unintended impacts of a pilot reform on Beijing’s zero markup drug policy: a propensity score-matched study

Impacts of Price Changes on Public Hospital Reforms in China: Evidence from 25 Million Patients at Tertiary Hospitals.

Changes of outpatient complaints before and after comprehensive reform of separation of drug sales from medical services in a 3A grade hospital in Beijing

Short-term and Long-Term Unintended Impacts of a Pilot Reform on Beijing's Zero Markup Drug Policy: a Propensity Score-Matched Study

How Government Insurance Coverage Changed the Utilization and Affordability of Expensive Targeted Anti-Cancer Medicines in China: an Interrupted Time-Series Study

Short-term and long-term effects of Sanming healthcare system reform on drug-related expenditures for rural patients with cancer in public hospitals: an interrupted time series analysis using segmented regression model in China

Does outpatient mutual‐aid reduce oncology patients' utilization of inpatient services?—An empirical study of outpatient mutual‐aid policy in Wuhan, China